Prolonging healthy aging: Longevity vitamins and proteins

I have a happy, healthy, youthful body. I do everything article suggests and have for 20+ years, also go to the gym 5x week. I’m 83, stronger than I’ve ever been. Shapely with excellent posture. Everything works, nothing hurts.

My very smart physician actually prescribes nutritional supplements for me. Eight per day. They are deductible, which is good because they are rather expensive. Most MDs are wedded to pharmaceutical companies, who finance medical schools.

Saw my doc last month and he said, “You’re very strong. You’ll live to be 100.”

So climb on the bandwagon, my fellow Freepers. You can do it too.

Veto!
(The girl)

And watch Dr. Berg’s videos on YouTube.

What nutritional supplements?. ..like Vitamin d3? I’d like to get some of the supplements I take covered!!

Bkmk

I will add St. John’s Wort to all that’s been “prescribed” so far. Keeping a positive attitude is also important to feeling youthful. I’ve been taking it for years. You don’t “notice” that it’s working at all, but when you go off it for awhile, little things begin to stress you out and you think: “Ohhhh so that’s what it does!”

I know many doubt the “herbals” ... But this one’s for real.

Actually, the second paragraph under “Abstract” gives the things to care about in the rest. You should be able to skim most of it until you find the unusual items (taurine, PQQ, ergotheionine, etc.).

Excellent, thanks.

I also suggest reading Wheat Belly, by William Davis, MD. and Grain Brain, by David Perlmutter, MD:
https://www.drperlmutter.com/about/grain-brain-by-david-perlmutter/

Perlmutter has a new book coming next year describing a somewhat different approach. He suggests eating only 2x per day, about 11:00 a.m. and 5 P.M, with protein at the evening meal because it takes 15 hours to completely absorb.
This is exactly what I’ve been doing for years, decades maybe. Have zero interest in food in the morning.

I took your article, transported it to Word and increased the type size so I can actually read it.

Thanks, will try. I do have one serious stressor. My young cat DaisyJane, a tri-colored tabby. Vet says tri-color tabbies are “very feisty.” Maybe I’ll give her St John’s Wort.

Thank you. Very helpful. Conclusion of author:

“I propose that an optimal level of many of the known 30 vitamins and essential minerals is necessary for promoting healthy aging.”

If a person wishes to live in a healthy way for many years, then he should review the 30 vitamins and minerals in the article.

2 of the 30 above include Vitamin D and Magnesium Citrate. Both are highly recommended by Dr. D. Eames and fitness pro F. Hahn.

Try different brands until you find one that does not make you tired. I personally like Nature’s Way brand. Sure, vitamins can be a waste of money. No need to take them every day. Once a week is fine. But certainly get D and Magnesium: two main ones.

Most of us are unwilling to wade through all of that, even if our lives depend on it...

I went through puberty in the 12th grade. This was very embarrassing and of course I was bullied. In sports, I never stood a chance. I hope I see a benefit in my older years.

It's a lot clearer with the footnotes

↵

Ames BN

(2006) Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proc Natl Acad Sci USA 103:17589–17594.

OpenUrl Abstract/FREE Full Text Google Scholar

↵
1. Hou Y,
2. Wu G
(2017) Nutritionally nonessential amino acids: A misnomer in nutritional sciences. Adv Nutr 8:137–139.
OpenUrl FREE Full Text Google Scholar
↵
1. Allen LH,
2. de Benoist B,
3. Dary O,
4. Hurrell RF
(2006) Guidelines on Food Fortification with Micronutrients (WHO, Geneva).
Google Scholar
↵
1. Mathias MG, et al.
(2018) Clinical and vitamin response to a short-term multi-micronutrient intervention in brazilian children and teens: From population data to interindividual responses. Mol Nutr Food Res 62:e1700613.
OpenUrl Google Scholar
↵
1. Drewnowski A,
2. Fulgoni VL 3rd
(2014) Nutrient density: Principles and evaluation tools. Am J Clin Nutr 99(Suppl):1223S–1228S.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Blumberg JB,
2. Frei B,
3. Fulgoni VL 3rd,
4. Weaver CM,
5. Zeisel SH
(2016) Vitamin and mineral intake is inadequate for most Americans: What should we advise patients about supplements? J Fam Pract 65(Suppl 9):S1–S8.
OpenUrl Google Scholar
↵
1. Fulgoni VL 3rd,
2. Keast DR,
3. Bailey RL,
4. Dwyer J
(2011) Foods, fortificants, and supplements: Where do Americans get their nutrients? J Nutr 141:1847–1854.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Papanikolaou Y,
2. Brooks J,
3. Reider C,
4. Fulgoni VL 3rd
(2014) U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: Results of an analysis using observational data from NHANES 2003-2008. Nutr J 13:31.
OpenUrl CrossRef PubMed Google Scholar
↵
1. McCann JC,
2. Ames BN
(2009) Vitamin K, an example of triage theory: Is micronutrient inadequacy linked to diseases of aging? Am J Clin Nutr 90:889–907.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. McCann JC,
2. Ames BN
(2011) Adaptive dysfunction of selenoproteins from the perspective of the triage theory: Why modest selenium deficiency may increase risk of diseases of aging. FASEB J 25:1793–1814.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Kirkwood TB,
2. Austad SN
(2000) Why do we age? Nature 408:233–238.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Patrick RP,
2. Ames BN
(2014) Vitamin D hormone regulates serotonin synthesis. Part 1: Relevance for autism. FASEB J 28:2398–2413.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Patrick RP,
2. Ames BN
(2015) Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: Relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB J 29:2207–2222.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Ramagopalan SV, et al.
(2010) A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. Genome Res 20:1352–1360.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Ames BN
(2003) The metabolic tune-up: Metabolic harmony and disease prevention. J Nutr 133(Suppl 1):1544S–1548S.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Ekwaru JP,
2. Zwicker JD,
3. Holick MF,
4. Giovannucci E,
5. Veugelers PJ
(2014) The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. PLoS One 9:e111265.
OpenUrl Google Scholar
↵
1. Grant WB, et al.
(2016) Do studies reporting ‘U’-shaped serum 25-hydroxyvitamin D-health outcome relationships reflect adverse effects? Dermatoendocrinol 8:e1187349.
OpenUrl Google Scholar
↵
1. Kojima G,
2. Iliffe S,
3. Tanabe M
(2017) Vitamin D supplementation as a potential cause of U-shaped associations between vitamin D levels and negative health outcomes: A decision tree analysis for risk of frailty. BMC Geriatr 17:236.
OpenUrl Google Scholar
↵
1. Veloudi P,
2. Jones G,
3. Sharman JE
(2017) Effectiveness of vitamin D supplementation for cardiovascular health outcomes. Pulse (Basel) 4:193–207.
OpenUrl Google Scholar
↵
1. Blumberg J, et al.
(2010) Evidence-based criteria in the nutritional context. Nutr Rev 68:478–484.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Michels AJ,
2. Frei B
(2013) Myths, artifacts, and fatal flaws: Identifying limitations and opportunities in vitamin C research. Nutrients 5:5161–5192.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Heaney RP
(2014) Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr Rev 72:48–54.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Smith GD,
2. Wimalawansa SJ
(2015) Reconciling the irreconcilable: Micronutrients in clinical nutrition and public health. Vitam Miner 4:e136.
OpenUrl Google Scholar
↵
1. Zeisel SH
(2015) How nutrigenetics can help prove that nutrient-based interventions reduce disease risk. Sight Life 29:60–63.
OpenUrl Google Scholar
↵
1. Brenner H,
2. Jansen L,
3. Saum KU,
4. Holleczek B,
5. Schöttker B
(2017) Vitamin D supplementation trials aimed at reducing mortality have much higher power when focusing on people with low serum 25-hydroxyvitamin D concentrations. J Nutr 147:1325–1333.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Grant WB,
2. Boucher BJ,
3. Bhattoa HP,
4. Lahore H
(2017) Why vitamin D clinical trials should be based on 25-hydroxyvitamin D concentrations. J Steroid Biochem Mol Biol 177:266–269.
OpenUrl Google Scholar
↵
1. Wagner CL,
2. Hollis BW,
3. Kotsa K,
4. Fakhoury H,
5. Karras SN
(2017) Vitamin D administration during pregnancy as prevention for pregnancy, neonatal and postnatal complications. Rev Endocr Metab Disord 18:307–322.
OpenUrl Google Scholar
↵
1. Scragg R
(2017) Limitations of vitamin D supplementation trials: Why observational studies will continue to help determine the role of vitamin D in health. J Steroid Biochem Mol Biol 177:6–9.
OpenUrl Google Scholar
↵
1. Guallar E,
2. Stranges S,
3. Mulrow C,
4. Appel LJ,
5. Miller ER 3rd
(2013) Enough is enough: Stop wasting money on vitamin and mineral supplements. Ann Intern Med 159:850–851.
OpenUrl PubMed Google Scholar
↵
1. Autier P,
2. Boniol M,
3. Pizot C,
4. Mullie P
(2014) Vitamin D status and ill health: A systematic review. Lancet Diabetes Endocrinol 2:76–89.
OpenUrl Google Scholar
↵
1. Offit PA
(2013) Do You Believe in Magic? The Sense and Nonsense of Alternative Medicine (HarperCollins, New York).
Google Scholar
↵
1. Harris WS, et al.
(2017) Red blood cell polyunsaturated fatty acids and mortality in the Women’s Health Initiative Memory Study. J Clin Lipidol 11:250–259.e5.
OpenUrl Google Scholar
↵
1. Chen GC,
2. Yang J,
3. Eggersdorfer M,
4. Zhang W,
5. Qin LQ
(2016) N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: A meta-analysis. Sci Rep 6:28165.
OpenUrl Google Scholar
↵
1. Lacombe RJS,
2. Chouinard-Watkins R,
3. Bazinet RP
(February 9, 2018) Brain docosahexaenoic acid uptake and metabolism. Mol Aspects Med doi:10.1016/j.mam.2017.12.004.
OpenUrl CrossRef Google Scholar
↵
1. Pawelczyk T, et al.
(2017) Omega-3 fatty acid supplementation may prevent loss of gray matter thickness in the left parieto-occipital cortex in first episode schizophrenia: A secondary outcome analysis of the OFFER randomized controlled study. Schizophr Res 195:168–175.
OpenUrl Google Scholar
↵
1. Farzaneh-Far R, et al.
(2010) Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA 303:250–257.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Kiecolt-Glaser JK, et al.
(2013) Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial. Brain Behav Immun 28:16–24.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Fiala M, et al.
(2015) ω-3 supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment. FASEB J 29:2681–2689.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Alexander DD,
2. Miller PE,
3. Van Elswyk ME,
4. Kuratko CN,
5. Bylsma LC
(2017) A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. Mayo Clin Proc 92:15–29.
OpenUrl CrossRef PubMed Google Scholar
↵
1. O’Keefe JH,
2. Jacob D,
3. Lavie CJ
(2017) Omega-3 fatty acid therapy: The tide turns for a fish story. Mayo Clin Proc 92:1–3.
OpenUrl Google Scholar
↵
1. Mahabir S, et al.
(2008) Dietary magnesium and DNA repair capacity as risk factors for lung cancer. Carcinogenesis 29:949–956.
OpenUrl CrossRef PubMed Google Scholar
↵
1. DiNicolantonio J,
2. O’Keefe J,
3. Wilson W
(2018) Subclinical magnesium deficiency: A principle driver of cardiovascular disease and a publice health crisis. Open Heart 5:1–16.
OpenUrl Google Scholar
↵
1. Rosanoff A,
2. Dai Q,
3. Shapses SA
(2016) Essential nutrient interactions: Does low or suboptimal magnesium status interact with vitamin D and/or calcium status? Adv Nutr 7:25–43.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Zeisel S
(2017) Choline, other methyl-donors and epigenetics. Nutrients 9:E445.
OpenUrl Google Scholar
↵
1. Wallace TC,
2. Fulgoni VL 3rd
(2016) Assessment of total choline intakes in the United States. J Am Coll Nutr 35:108–112.
OpenUrl Google Scholar
↵
1. Zeisel SH
(2006) The fetal origins of memory: The role of dietary choline in optimal brain development. J Pediatr 149(Suppl):S131–S136.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Zeisel SH
(2012) Diet-gene interactions underlie metabolic individuality and influence brain development: Implications for clinical practice derived from studies on choline metabolism. Ann Nutr Metab 60:19–25.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Zeisel SH
(2012) Dietary choline deficiency causes DNA strand breaks and alters epigenetic marks on DNA and histones. Mutat Res 733:34–38.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Bouckenooghe T,
2. Remacle C,
3. Reusens B
(2006) Is taurine a functional nutrient? Curr Opin Clin Nutr Metab Care 9:728–733.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Huxtable RJ
(1992) Physiological actions of taurine. Physiol Rev 72:101–163.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Wójcik OP,
2. Koenig KL,
3. Zeleniuch-Jacquotte A,
4. Costa M,
5. Chen Y
(2010) The potential protective effects of taurine on coronary heart disease. Atherosclerosis 208:19–25.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Suzuki T,
2. Nagao A,
3. Suzuki T
(2011) Human mitochondrial diseases caused by lack of taurine modification in mitochondrial tRNAs. Wiley Interdiscip Rev RNA 2:376–386.
OpenUrl Google Scholar
↵
1. Takahashi Y,
2. Hatta H
(2017) Effects of taurine administration on exercise-induced fatigue and recovery. J Phys Fit Sports Med 6:33–39.
OpenUrl Google Scholar
↵
1. Hansen SH,
2. Andersen ML,
3. Cornett C,
4. Gradinaru R,
5. Grunnet N
(2010) A role for taurine in mitochondrial function. J Biomed Sci 17:S23.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Jong CJ,
2. Azuma J,
3. Schaffer S
(2012) Mechanism underlying the antioxidant activity of taurine: Prevention of mitochondrial oxidant production. Amino Acids 42:2223–2232.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Schuller-Levis GB,
2. Park E
(2004) Taurine and its chloramine: Modulators of immunity. Neurochem Res 29:117–126.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Dypbukt JM, et al.
(2005) A sensitive and selective assay for chloramine production by myeloperoxidase. Free Radic Biol Med 39:1468–1477.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Sun Q, et al.
(2016) Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: Randomized, double-blind, placebo-controlled study. Hypertension 67:541–549.
OpenUrl Google Scholar
↵
1. Yamori Y, et al.
(2009) Taurine as the nutritional factor for the longevity of the Japanese revealed by a world-wide epidemiological survey. Adv Exp Med Biol 643:13–25.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Xu YJ,
2. Arneja AS,
3. Tappia PS,
4. Dhalla NS
(2008) The potential health benefits of taurine in cardiovascular disease. Exp Clin Cardiol 13:57–65.
OpenUrl PubMed Google Scholar
↵
1. Li XW,
2. Gao HY,
3. Liu J
(2017) The role of taurine in improving neural stem cells proliferation and differentiation. Nutr Neurosci 20:409–415.
OpenUrl Google Scholar
↵
1. O’Donnell CP, et al.
(2016) Adjunctive taurine in first-episode psychosis: A phase 2, double-blind, randomized, placebo-controlled study. J Clin Psychiatry 77:e1610–e1617.
OpenUrl Google Scholar
↵
1. Ito T,
2. Schaffer SW,
3. Azuma J
(2012) The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids 42:1529–1539.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Sarkar P,
2. Basak P,
3. Ghosh S,
4. Kundu M,
5. Sil PC
(2017) Prophylactic role of taurine and its derivatives against diabetes mellitus and its related complications. Food Chem Toxicol 110:109–121.
OpenUrl Google Scholar
↵
1. Hansen SH
(2001) The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev 17:330–346.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Bianchi L, et al.
(2012) Taurine transporter gene expression in peripheral mononuclear blood cells of type 2 diabetic patients. Amino Acids 42:2267–2274.
OpenUrl PubMed Google Scholar
↵
1. Napoli Z, et al.
(2016) Taurine transporter gene expression in mononuclear blood cells of type 1 diabetes patients. J Diabetes Res 2016:7313162.
OpenUrl Google Scholar
↵
1. Clark GJ,
2. Pandya K,
3. Lau-Cam CA
(2017) The effect of metformin and taurine, alone and in combination, on the oxidative stress caused by diabetes in the rat brain. Adv Exp Med Biol 975:353–369.
OpenUrl Google Scholar
↵
1. Patel SN,
2. Lau-Cam CA
(2017) The effect of taurine and its immediate homologs on diabetes-induced oxidative stress in the brain and spinal cord of rats. Adv Exp Med Biol 975:337–351.
OpenUrl Google Scholar
↵
1. Arany E
(2017) Maternal taurine supplementation prevents misprogramming. Diet, Nutrition, and Fetal Programming. Nutrition and Health, eds Rajendram R, Preedy V, Patel V (Humana Press, Cham, Switzerland), pp 309–324.
Google Scholar
↵
1. Schaffer SW,
2. Jong CJ,
3. Ramila KC,
4. Azuma J
(2010) Physiological roles of taurine in heart and muscle. J Biomed Sci 17:S2.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Kalaras MD,
2. Richie JP,
3. Calcagnotto A,
4. Beelman RB
(2017) Mushrooms: A rich source of the antioxidants ergothioneine and glutathione. Food Chem 233:429–433.
OpenUrl Google Scholar
↵
1. Seebeck FP
(2010) In vitro reconstitution of mycobacterial ergothioneine biosynthesis. J Am Chem Soc 132:6632–6633.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Pfeiffer C,
2. Bauer T,
3. Surek B,
4. Schömig E,
5. Gründemann D
(2011) Cyanobacteria produce high levels of ergothioneine. Food Chem 129:1766–1769.
OpenUrl CrossRef Google Scholar
↵
1. Ramirez-Martinez A,
2. Wesolek N,
3. Yadan J-C,
4. Moutet M,
5. Roudot A-C
(2016) Intake assessment of L-ergothioneine in some european countires and in the United States. Hum Ecol Risk Assess 22:667–677.
OpenUrl Google Scholar
↵
1. Ey J,
2. Schömig E,
3. Taubert D
(2007) Dietary sources and antioxidant effects of ergothioneine. J Agric Food Chem 55:6466–6474.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Hartman PE
(1990) Ergothioneine as antioxidant. Methods Enzymol 186:310–318.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Franzoni F, et al.
(2006) An in vitro study on the free radical scavenging capacity of ergothioneine: Comparison with reduced glutathione, uric acid and trolox. Biomed Pharmacother 60:453–457.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Cheah IK,
2. Tang RM,
3. Yew TS,
4. Lim KH,
5. Halliwell B
(2017) Administration of pure ergothioneine to healthy human subjects: Uptake, metabolism, and effects on biomarkers of oxidative damage and inflammation. Antioxid Redox Signal 26:193–206.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Servillo L,
2. DʼOnofrio N,
3. Balestrieri ML
(2017) Ergothioneine antioxidant function: From chemistry to cardiovascular therapeutic potential. J Cardiovasc Pharmacol 69:183–191.
OpenUrl Google Scholar
↵
1. Cheah IK,
2. Feng L,
3. Tang RMY,
4. Lim KHC,
5. Halliwell B
(2016) Ergothioneine levels in an elderly population decrease with age and incidence of cognitive decline; a risk factor for neurodegeneration? Biochem Biophys Res Commun 478:162–167.
OpenUrl Google Scholar
↵
1. Halliwell B,
2. Cheah IK,
3. Drum CL
(2016) Ergothioneine, an adaptive antioxidant for the protection of injured tissues? A hypothesis. Biochem Biophys Res Commun 470:245–250.
OpenUrl Google Scholar
↵
1. Taubert D, et al.
(2006) Association of rheumatoid arthritis with ergothioneine levels in red blood cells: A case control study. J Rheumatol 33:2139–2145.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Paul BD,
2. Snyder SH
(2010) The unusual amino acid L-ergothioneine is a physiologic cytoprotectant. Cell Death Differ 17:1134–1140.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Gründemann D, et al.
(2005) Discovery of the ergothioneine transporter. Proc Natl Acad Sci USA 102:5256–5261.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Gründemann D
(2012) The ergothioneine transporter controls and indicates ergothioneine activity—A review. Prev Med 54:S71–S74.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Mathieson I, et al.
(2015) Genome-wide patterns of selection in 230 ancient Eurasians. Nature 528:499–503.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Peltekova VD, et al.
(2004) Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 36:471–475.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Jung ES,
2. Park HJ,
3. Kong KA,
4. Choi JH,
5. Cheon JH
(2017) Association study between OCTN1 functional haplotypes and Crohn’s disease in a Korean population. Korean J Physiol Pharmacol 21:11–17.
OpenUrl Google Scholar
↵
1. Kato Y, et al.
(2010) Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1. Pharm Res 27:832–840.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Pfeiffer C, et al.
(2015) Knockout of the ergothioneine transporter ETT in zebrafish results in increased 8-oxoguanine levels. Free Radic Biol Med 83:178–185.
OpenUrl Google Scholar
↵
1. Rucker R,
2. Chowanadisai W,
3. Nakano M
(2009) Potential physiological importance of pyrroloquinoline quinone. Altern Med Rev 14:268–277.
OpenUrl PubMed Google Scholar
↵
1. Klinman JP,
2. Bonnot F
(2014) Intrigues and intricacies of the biosynthetic pathways for the enzymatic quinocofactors: PQQ, TTQ, CTQ, TPQ, and LTQ. Chem Rev 114:4343–4365.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Kumazawa T,
2. Sato K,
3. Seno H,
4. Ishii A,
5. Suzuki O
(1995) Levels of pyrroloquinoline quinone in various foods. Biochem J 307:331–333.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Choi O, et al.
(2008) Pyrroloquinoline quinone is a plant growth promotion factor produced by Pseudomonas fluorescens B16. Plant Physiol 146:657–668.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Itoh Y, et al.
(2016) Effect of the antioxidant supplement pyrroloquinoline quinone disodium salt (BioPQQ™) on cognitive functions. Adv Exp Med Biol 876:319–325.
OpenUrl Google Scholar
↵
1. Harris CB, et al.
(2013) Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects. J Nutr Biochem 24:2076–2084.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Akagawa M, et al.
(2016) Identification of lactate dehydrogenase as a mammalian pyrroloquinoline quinone (PQQ)-binding protein. Sci Rep 6:26723.
OpenUrl Google Scholar
↵
1. Stites T, et al.
(2006) Pyrroloquinoline quinone modulates mitochondrial quantity and function in mice. J Nutr 136:390–396.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Chowanadisai W, et al.
(2010) Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. J Biol Chem 285:142–152.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Nishimura S
(1983) Structure, biosynthesis, and function of queuosine in transfer RNA. Prog Nucleic Acid Res Mol Biol 28:49–73.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Fergus C,
2. Barnes D,
3. Alqasem MA,
4. Kelly VP
(2015) The queuine micronutrient: Charting a course from microbe to man. Nutrients 7:2897–2929.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Farkas WR
(1980) Effect of diet on the queuosine family of tRNAs of germ-free mice. J Biol Chem 255:6832–6835.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Reyniers JP,
2. Pleasants JR,
3. Wostmann BS,
4. Katze JR,
5. Farkas WR
(1981) Administration of exogenous queuine is essential for the biosynthesis of the queuosine-containing transfer RNAs in the mouse. J Biol Chem 256:11591–11594.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Boland C,
2. Hayes P,
3. Santa-Maria I,
4. Nishimura S,
5. Kelly VP
(2009) Queuosine formation in eukaryotic tRNA occurs via a mitochondria-localized heteromeric transglycosylase. J Biol Chem 284:18218–18227.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Rakovich T, et al.
(2011) Queuosine deficiency in eukaryotes compromises tyrosine production through increased tetrahydrobiopterin oxidation. J Biol Chem 286:19354–19363.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Watschinger K, et al.
(2015) Tetrahydrobiopterin and alkylglycerol monooxygenase substantially alter the murine macrophage lipidome. Proc Natl Acad Sci USA 112:2431–2436.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Alrayes N, et al.
(2016) The alkylglycerol monooxygenase (AGMO) gene previously involved in autism also causes a novel syndromic form of primary microcephaly in a consanguineous Saudi family. J Neurol Sci 363:240–244.
OpenUrl Google Scholar
↵
1. Frye RE
(2014) Tetrahydrobiopterin deficiency in autism spectrum disorder. N Am J Med Sci (Boston) 7:93–96.
OpenUrl Google Scholar
↵
1. Burton B, et al.
(2015) A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria. Mol Genet Metab 114:415–424.
OpenUrl Google Scholar
↵
1. Frye RE
(2015) Metabolic and mitochondrial disorders associated with epilepsy in children with autism spectrum disorder. Epilepsy Behav 47:147–157.
OpenUrl Google Scholar
↵
1. Marks T,
2. Farkas WR
(1997) Effects of a diet deficient in tyrosine and queuine on germfree mice. Biochem Biophys Res Commun 230:233–237.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Varghese S, et al.
(2017) In vivo modification of tRNA with an artificial nucleobase leads to full disease remission in an animal model of multiple sclerosis. Nucleic Acids Res 45:2029–2039.
OpenUrl Google Scholar
↵
1. Klotz LO,
2. Kröncke KD,
3. Sies H
(2003) Singlet oxygen-induced signaling effects in mammalian cells. Photochem Photobiol Sci 2:88–94.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Institute of Medicine
(2000) Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids (National Academy Press, Washington, DC).
Google Scholar
↵
1. Scott-Boyer MP, et al.
(2016) A network analysis of cofactor-protein interactions for analyzing associations between human nutrition and diseases. Sci Rep 6:19633.
OpenUrl Google Scholar
↵
1. Blumberg JB,
2. Bailey RL,
3. Sesso HD,
4. Ulrich CM
(2018) The evolving role of multivitamin/multimineral supplement use among adults in the age of personalized nutrition. Nutrients 10:E248.
OpenUrl Google Scholar
↵
1. Lim SS, et al.
(2012) A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2224–2260.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Bao Y, et al.
(2013) Association of nut consumption with total and cause-specific mortality. N Engl J Med 369:2001–2011.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Micha R, et al.
(2017) Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. JAMA 317:912–924.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Schwingshackl L, et al.
(2017) Dietary supplements and risk of cause-specific death, cardiovascular disease, and cancer: A systematic review and meta-analysis of primary prevention trials. Adv Nutr 8:27–39.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Shlisky J, et al.
(2017) Nutritional considerations for healthy aging and reduction in age-related chronic disease. Adv Nutr 8:17–26.
OpenUrl Abstract Google Scholar
↵
1. Ewald P
(2002) Plague Time: The New Gem Theory of Disease (Anchor Books, New York).
Google Scholar
↵
1. Bourke CD,
2. Berkley JA,
3. Prendergast AJ
(2016) Immune dysfunction as a cause and consequence of malnutrition. Trends Immunol 37:386–398.
OpenUrl CrossRef PubMed Google Scholar
↵
1. García OP,
2. Long KZ,
3. Rosado JL
(2009) Impact of micronutrient deficiencies on obesity. Nutr Rev 67:559–572.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Damms-Machado A,
2. Weser G,
3. Bischoff SC
(2012) Micronutrient deficiency in obese subjects undergoing low calorie diet. Nutr J 11:34.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Via M
(2012) The malnutrition of obesity: Micronutrient deficiencies that promote diabetes. ISRN Endocrinol 2012:103472.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Amara NB, et al.
(2014) Multivitamin restriction increases adiposity and disrupts glucose homeostasis in mice. Genes Nutr 9:410.
OpenUrl Google Scholar
↵
1. Agarwal S,
2. Reider C,
3. Brooks JR,
4. Fulgoni VL 3rd
(2015) Comparison of prevalence of inadequate nutrient intake based on body weight status of adults in the United States: An analysis of NHANES 2001-2008. J Am Coll Nutr 34:126–134.
OpenUrl CrossRef PubMed Google Scholar
↵
1. McCann JC, et al.
(2015) A multicomponent nutrient bar promotes weight loss and improves dyslipidemia and insulin resistance in the overweight/obese: Chronic inflammation blunts these improvements. FASEB J 29:3287–3301.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Arnold M,
2. Renehan AG,
3. Colditz GA
(2017) Excess weight as a risk factor common to many cancer sites: Words of caution when interpreting meta-analytic evidence. Cancer Epidemiol Biomarkers Prev 26:663–665.
OpenUrl FREE Full Text Google Scholar
↵
1. Ajala O,
2. Mold F,
3. Boughton C,
4. Cooke D,
5. Whyte M
(2017) Childhood predictors of cardiovascular disease in adulthood. A systematic review and meta-analysis. Obes Rev 18:1061–1070.
OpenUrl PubMed Google Scholar
↵
1. Caleyachetty R, et al.
(2017) Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol 70:1429–1437.
OpenUrl FREE Full Text Google Scholar
↵
1. Lassale C, et al.
(2017) Separate and combined associations of obesity and metabolic health with coronary heart disease: A pan-European case-cohort analysis. Eur Heart J 39:397–406.
OpenUrl Google Scholar
↵
1. McIntyre RS, et al.
(2017) Adverse effects of obesity on cognitive functions in individuals at ultra high risk for bipolar disorder: Results from the global mood and brain science initiative. Bipolar Disord 19:128–134.
OpenUrl Google Scholar
↵
1. Rhea EM, et al.
(2017) Blood-brain barriers in obesity. AAPS J 19:921–930.
OpenUrl Google Scholar
↵
1. Stillman CM,
2. Weinstein AM,
3. Marsland AL,
4. Gianaros PJ,
5. Erickson KI
(2017) Body-brain connections: The effects of obesity and behavioral interventions on neurocognitive aging. Front Aging Neurosci 9:115.
OpenUrl Google Scholar
↵
1. Saltiel AR,
2. Olefsky JM
(2017) Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest 127:1–4.
OpenUrl CrossRef PubMed Google Scholar
↵
1. Gonzales GB, et al.
(2015) Flavonoid interactions during digestion, absorption, distribution and metabolism: A sequential structure-activity/property relationship-based approach in the study of bioavailability and bioactivity. Drug Metab Rev 47:175–190.
OpenUrl Google Scholar
↵
1. Ames BN,
2. Profet M,
3. Gold LS
(1990) Dietary pesticides (99.99% all natural). Proc Natl Acad Sci USA 87:7777–7781.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Saul N,
2. Pietsch K,
3. Stürzenbaum SR,
4. Menzel R,
5. Steinberg CE
(2013) Hormesis and longevity with tannins: Free of charge or cost-intensive? Chemosphere 93:1005–1008.
OpenUrl Google Scholar
↵
1. Nelson JW,
2. Breaker RR
(2017) The lost language of the RNA world. Sci Signal 10:eaam8812.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Ames BN,
2. Elson-Schwab I,
3. Silver EA
(2002) High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): Relevance to genetic disease and polymorphisms. Am J Clin Nutr 75:616–658.
OpenUrl Abstract/FREE Full Text Google Scholar
↵
1. Kaput J,
2. Rodriguez R
1. Ames BN,
2. Suh JH,
3. Liu J
(2006) Enzymes lose binding affinity (increase Km) for coenzymes and substrates with age: A strategy for remediation. Nutrigenomics: Discovering the Path to Personalized Nutrition, eds Kaput J, Rodriguez R (John Wiley & Sons, Hoboken, NJ), pp 277–293.
Google Scholar
↵
1. Liu J,
2. Atamna H,
3. Kuratsune H,
4. Ames BN
(2002) Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann N Y Acad Sci 959:133–166.
OpenUrl PubMed Google Scholar
↵
1. Höller U, et al.
(2018) Micronutrient status assessment in humans: Current methods of analysis and future trends. Trends Analyt Chem 102:110–122.
OpenUrl Google Scholar
↵
1. Food Supplements Europe
(2017) Healthcare cost savings of calcium and vitamin D food supplements in the European Union (Frost & Sullivan, Mountain View, CA).
Google Scholar
↵
1. Willett WC
(2013) Nutritional Epidemiology (Oxford Univ Press, New York), 3rd Ed.
Google Scholar

Yes, D3, but only the best quality. I’ll dig my list out tomorrow and post it here. Late now, tired.

The industry (supplements) as a whole is very scammy ... just like say, MOST religion ‘sold’ around the world is a scam. But that doesn’t mean that religion is a scam ... just that there’s a lot of scam around it.

Bookmark

The article let me post the whole thing.

We have others on Free Republic that claim the whole article should be posted, when possible.

Reference/health bump - waiting for executive summary bump!

Correct.

AND exercise.

Thanks for the post and link. This is a good review.

I am going to present four abstracts at the Movements Disorders meeting in Nice this fall. We have been investigating neurodegeneration involving disregulation of the Cupin superfamily and the metabolic "cycle" involved in human health and aging.

Taurine is a major end product in both the exogenous and endogenous pathways. The author was somewhat correct on the pathways to taurine.

We have focused deeply on these pathways because of a rare gene mutation that attacks children. During the research we realized that the disorder was the Rosetta Stone for neurodegeneration.

Taurine deficiency is a serious problem in human aging as well as numerous diseases, however the upstream metabolites that convert to taurine are far more critical for the prevention of neurodegeneration. These are cysteamine and hypotaurine. Hypotaurine is produced from two different dioxygenase pathways to taurine. One is cysteine and the other cysteamine. Both cysteramine and hypotaurine are necessary reactive oxygen species scavengers in the brain, whereas taurine is not.

The cysteamine part of the cycle is the endogenous portion from the breakdown of coenzyme A. This is being researched now in Parkinson's and Huntington's disease. The initial Huntington's RCT failed to show disease reversal, however it was too short. It did show a dramatic increase in brain derived neurotrophic factor (BDNF). This was probably the most important finding.

The cysteine portion is more of an exogenous pathway to hypotaurine and taurine. Cysteine can be increased by dietary intake such as eggs or by supplement with NAC.

We have found an older metabolite that fulfills the endogenous part of the cycle. This is Pantethine and has been researched for almost 60 years (well over 600 papers and hundreds of RCTs). It was the frontline hypercholesterolemia agent prior to statins. Further, pantethine lowered LDL, raised HDL, lowered triglycerides and improved platelet clotting function. It did not lower LDL as much as statins. That was the marketing appeal of statins. Unlike statins, Pantethine's action did not involve the disruption of the mevalonate pathway. Pantethine breaks down after oral ingestion in the lumina of the intestine to pantothenate and cysteamine. Cysteamine is the critical agent to support the endogenous portion of the hypotaurine to taurine pathway. Both cysteamine and pantethine have shown other therapeutic benefits including protection in malaria infection, radiation treatment and brain infarct.

Sadly, because of statin marketing, pantethine research has slowed dramatically in the past 15 years. This is tragic for those suffering from metabolic disorders and those who are also taking statins. I will go on record as saying when the time comes, statins will be seen as the worse of bad drugs. The controversy over Vioxx and Tamiflu will pale in comparison. The first lawsuits have already been filed over statin caused type 2 diabetes. The longterm neurological damage has yet to be assessed.

I am not a doctor and this is not medical advice. Pantethine can be found on Amazon (active agent Pantesin). My wife and I began taking it three years ago at a dose of 450mg TID.

I'll be able to post much more after the meeting and also our submissions of other IRBs and NIH R01 applications.

For those who are interested in problems with disrupting the mevalonate pathway there is this link: Statin Damage to the Mevalonate Pathway.

Did not see Jack Daniels anywhere.